Mvasi Indications/Uses

Metastatic Colorectal Cancer (mCRC): MVASI (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Metastatic Breast Cancer (mBC): MVASI in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.
Advanced, metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC): MVASI, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer.
Advanced and/or metastatic Renal Cell Cancer (mRCC): MVASI in combination with interferon alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell cancer.
Glioblastoma: MVASI is indicated for the treatment of glioblastoma with progressive disease following prior therapy as single agent.
The effectiveness of MVASI in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with MVASI.
Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer: MVASI, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (FIGO* stages III B, III C, and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
MVASI, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF*-targeted angiogenesis inhibitors.
MVASI in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
*FIGO: International Federation of Gynaecology and Obstetrics
*VEGF: Vascular Endothelial Growth Factor
Cervical Cancer: MVASI in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for the treatment of persistent, recurrent, or metastatic carcinoma of the cervix.